Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM01HLX)

Drug Name
GR-127935 Drug Info
Synonyms
148672-13-3; GR 127935; GR-127935; N-(4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide; GR127935; UNII-2LLH6CEB40; 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; 2LLH6CEB40; CHEMBL15928; GR 127935 hydrochloride hydrate; N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE; CHEBI:64114; GR 127935 HCl; C29H31N5O3
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Terminated [1] , [2]
Cross-matching ID
PubChem CID
107780
ChEBI ID
CHEBI:64114
CAS Number
CAS 148672-13-3
TTD Drug ID
DM01HLX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [4]
Eletriptan DMW649X Migraine 8A80 Approved [5]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [5]
Frovatriptan DM7RE8P Migraine 8A80 Approved [5]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [5]
Naratriptan DMO50U2 Migraine 8A80 Approved [6]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [5]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [7]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [8]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [10]
Eletriptan DMW649X Migraine 8A80 Approved [5]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [5]
Frovatriptan DM7RE8P Migraine 8A80 Approved [5]
Sumatriptan DMVYXR8 Migraine 8A80 Approved [11]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [12]
Almogran DM7I64Z Migraine 8A80 Approved [13]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [14]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [15]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [3]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Modulator [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 14).
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002743)
3 GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61.
4 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
7 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
8 Company report (NeurAxon)
9 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
10 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
11 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
12 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
13 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
14 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)